Document ID: chunk:federal_register_of_legislation:F2025C00183:clause:1_73072
Version: federal_register_of_legislation:F2025C00183
Segment Type: clause
Provision Reference: sch 1 cl 73072
Character Range: 260020–261409

73072              A test, including partial genotyping, for oncogenic human papillomavirus:                                                                                                                                                                                                                                                                                                          35.00
                   (a) for the investigation of a patient in a specific population that appears to have a higher risk of cervical pre‑cancer or cancer; or
                   (b) for the follow‑up management of a patient with a previously detected oncogenic human papillomavirus infection or cervical pre‑cancer or cancer; or
                   (c) for the investigation of a patient with symptoms suggestive of cervical cancer; or
                   (d) for the follow‑up management of a patient after treatment of high grade squamous intraepithelial lesions or adenocarcinoma in situ of the cervix; or
                   (e) for the follow‑up management of a patient with glandular abnormalities; or
                   (f) for the follow‑up management of a patient exposed to diethylstilboestrol in utero; or
                   (g) for a patient previously treated for a genital tract malignancy when performed as a co‑test for both human papillomavirus (HPV) and liquid‑based cytology (LBC)